چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده ثبت کننده مقاله | نعیمه مصری علمداری |
| مرحله جاری مقاله | تایید نهایی |
| دانشکده/مرکز مربوطه | مرکز تحقیقات غدد درون ریز |
| کد مقاله | 86520 |
| عنوان فارسی مقاله | The cardio metabolic and glycemic effects of empagliflozin and sitagliptin in Type 2 Diabetes adults: Results from a clinical trial |
| عنوان لاتین مقاله | The cardio metabolic and glycemic effects of empagliflozin and sitagliptin in Type 2 Diabetes adults: Results from a clinical trial |
| نوع ارائه | پوستر |
| عنوان کنگره / همایش | نهمین کنگره ملی پیشگیری و درمان چاقی ایران |
| نوع کنگره / همایش | ملی |
| کشور محل برگزاری کنگره/ همایش | Iran (Islamic Republic) |
| شهر محل برگزاری کنگره/ همایش | تهران |
| سال انتشار/ ارائه شمسی | 1403 |
| سال انتشار/ارائه میلادی | 2024 |
| تاریخ شمسی شروع و خاتمه کنگره/همایش | 1403/09/28 الی 1403/10/30 |
| آدرس لینک مقاله/ همایش در شبکه اینترنت | https://www.obesitycongress.ir/fa/ |
| آدرس علمی (Affiliation) نویسنده متقاضی | Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. |
| نویسنده | نفر چندم مقاله |
|---|---|
| مریم برغمان | دوم |
| ندا روشن روان | سوم |
| وحیده صدرا | چهارم |
| نعیمه مصری علمداری | اول |
| عنوان | متن |
|---|---|
| کلمات کلیدی | Empagliflozin, Fasting plasma glucose, HbA1c, Metformin, Sitagliptin, Type 2 diabetes |
| خلاصه مقاله | Background and Aims: To evaluate the effects of empagliflozin and sitagliptin along with metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus(T2DM). Material and Methods: T2DM patients with a randomized, double-blind design and three arms including empagliflozin 10 mg (n=50) arm, sitagliptin 100 mg (n=50) arm, and metformin 1000 mg (n=50) arm were assessed. Glycosylated hemoglobin (HbA1c, %), fasting blood sugar (FBS)(mg/d), body weight (kg), Systolic blood pressure (SBP), Diastolic blood pressure(DBP), and lipid profile were assessed at the beginning of the study and following 12 weeks. Results: Empagliflozin resulted in a noticeable decrement of Hb A1c and FBS levels in comparison to the metformin group during 12 weeks of intervention (P= 0.027, P=0.037 respectively). A striking devaluation of body weight in the empagliflozin receiving group relative to the metformin receiving group was reported (P=0.044). TG levels were remarkably diminished in comparison with the metformin treatment group (P=0.041). Empagliflozin but not sitagliptin resulted in reductions of SBP and DBP relative to the metformin arm (P= 0.001, P=0.001). Conclusion: Empagliflozin 10 mg besides the metformin in T2DM patients has beneficial impacts on cardiometabolic factors through improvement of glycemic indices, SBP, DBP, TG, and weight. It is suggested that empagliflozin 10 mg adjacent to metformin was superior to sitagliptin for cardio metabolic factors in T2DM. More, investigations are necessary to approve and discover the mechanistic underlying pathways. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| article.docx | 1403/10/18 | 16437 | دانلود |
| empagliphlozin.pdf | 1403/10/18 | 722224 | دانلود |
